Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 113

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 113
---
 express no such opinion.

Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ MaloneBailey, LLP

www.malonebailey.com

We have served as the Company's auditor since 2024.

Houston, Texas

March 31, 2025

F-2

DRUGS MADE IN AMERICA ACQUISITION CORP.

BALANCE SHEET

DECEMBER 31, 2024

    ASSETS 

    Current assets 

    Cash 
    $1,351 
  
    Prepaid expenses and other current assets 
     3,640 
  
    Total Current Assets 
     4,991 
  
    Deferred offering costs 
     545,833 
  
    Total Assets 
    $550,824 

    LIABILITIES AND SHAREHOLDERS’ DEFICIT 

    Current liabilities: 

    Accrued expenses 
    $77,280 
  
    Accrued offering costs 
     56,065 
  
    Promissory note - related party 
     662,324 
  
    Total Liabilities 
     795,669 

    Commitments and contingencies 

    Shareholders’ Deficit: 

    Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding 
     — 
  
    Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 9,857,143 shares issued and outstanding(1)(2) 
     986 
  
    Additional paid-in capital 
     34,014 
  
    Accumulated deficit 
     (279,845)
  
    Total Shareholders’ Deficit 
     (244,845)
  
    Total Liabilities and Shareholders’ Deficit 
    $550,824 

  (1) Includes an aggregate of up to 1,285,714 ordinary shares subject to surrender
and forfeiture if the over-allotment option is not exercised in full